Chairman and Non-Executive Director
Mr. Lynch joined Evofem Biosciences, as Chairman and Non-Executive Director in 2015. Mr. Lynch graduated with a BSc in Economics from Queen’s University in Belfast and subsequently qualified as a chartered accountant in 1983 from the Institute of Chartered Accountants in Ireland.
Mr. Lynch is a member of the board of GW Pharma plc and chair of the Ireland East Hospital Group. From 2013 to 2016, Mr. Lynch served as the non-executive chairman of the board of directors of Icon plc, a leading provider of clinical research services.
Mr. Lynch practiced as a charted accountant with KPMG from 1983 to 1993, commencing as an audit assistant at KPMG in 1980, prior to qualification. Following his time at KPMG, Mr. Lynch founded Warner Chilcott, where he was a director of the company until 2002. Simultaneously, Mr. Lynch was Chief Financial Officer at Elan Corporation plc from 1993 to 2000. Since 2006, Mr. Lynch has held several pro-bono directorships, including at the Institute of Human Virology, UMBI, Baltimore, Maryland; the Trinity Biological Sciences Institute, Molecular Medicine, Ireland; the Dublin Academic Medical Centre; and Mater Misericordiae University Hospital, Dublin, Ireland.
Ms. Douglas joined Evofem Biosciences as a Non-Executive Director in 2015. Ms. Douglas started in 1999 as a Sales and Marketing Manager at IDIS Ltd in the United Kingdom. After promotions from Manager to Director, to Managing Director, and spending some time at IDIS, Inc. USA, Ms. Douglas became Chief Executive Officer of IDIS Ltd, UK in 2010. Subsequently, from January to May 2014, Ms. Douglas was Co-Founder, Partner, and Chairman of Rocket Science Consultancy, New York. Since May 2014, Ms. Douglas is CEO for Healthcare at Home Limited in the United Kingdom.
She graduated in 1992 with a Chartered Institute of Marketing Certificate and, subsequently, in 1995 with a Chartered Institute of Marketing Diploma, both from Thames Valley University, London. Finally, in 1997, Ms. Douglas concluded a Masters in Marketing Management from Middlesex University, London.
Mr. Rutherford joined Evofem Biosciences as a Non-Executive Director in 2015. He graduated in Accountancy and Finance from Heriot Watt University and qualified as a chartered accountant with Touche Ross in 1984.
Mr. Rutherford has been involved in turning around numerous companies. In 2002, he assisted on the restructuring and sale of Euro Sales Finance plc, a London-listed specialty finance business with 18 offices across Europe and revenues of £4 billion. Mr. Rutherford was also involved in the restructuring and rebranding of Noble House Pub Group Limited. Noble House Pub Group Limited became Pioneer Pub Group Limited and was later sold for £169 million in 2006. Mr. Rutherford also has offshore experience working as the Chairman of SGI/Circus Capital Fund (a specialist asset management company) based in Guernsey, Cayman Islands, and Hong Kong, developing its product range from 2004 to 2009.
More recently, Mr. Rutherford worked for European Healthcare Group as Non-Executive Chairman from 2012 to 2014 until its acquisition by two hedge funds. Mr. Rutherford also worked as Chief Executive Officer and Chairman to restructure MAM Funds plc, which had significant debt.
As well as positions on various boards, Mr. Rutherford is independent chairman of Brookgate, working with Microsoft and ARU on a large mixed-use property development project with a conservative estimated value of £75 million. He also sits on the board of Mitchells & Butlers plc, a leisure group with over 1600 outlets and revenue approaching £2 billion.
Simon Best, OBE, FRSE
Prof. Simon Best is a Founder, CEO, and Chairman or Board Member of life science companies and a Chairman or Trustee of institutions in the UK, USA, Europe, Asia, and Latin America, including the UK BioIndustry Association, the US Biotechnology Industry Organization, the International Potato Centre, and the Edinburgh International Festival. His entrepreneurial achievements include Ardana plc, which as founding CEO, he built from an academic spin-out of the Medical Research Council Human Reproductive Science Unit to a UK public company thatwas listed on the LSE in 2005.
He is also an experienced investor and in 2009, as a Partner and Entrepreneur-in-Residence of the TVM Capital MENA Fund in UAE and India, originated the founding funding-round for the International arm of the leading infertility clinic Bourn Hall, where Nobel Prize winner Prof. Robert Edwards invented and first commercialized human IVF technology. Prof. Best is currently the Chairman of Canadian rare disease company ProMetic Lifesciences Inc.
Thomas Darden II
Mr. Darden has been a Director and Stockholder of Evofem Biosciences from its inception. He began his career as an environmental planner for the Korea Institute of Science and Technology before working as a consultant with Bain & Company in Boston. From 1984 to 2000, Mr. Darden served as the Chairman of Cherokee Sanford Group, a large brick manufacturing company and is the Founding Partner at Cherokee Ventures LLC. Mr. Darden is also CEO and Founder of Cherokee Investment Partners, a private equity fund that invests in real estate projects renovating brownfield sites.
Mr. Darden holds a BA in anthropology and a Masters in regional planning from the University of North Carolina at Chapel Hill and a Juris Doctor from Yale University. He sits on the boards of Shaw University and the Institute of the Environment at the University of North Carolina, and serves on the Board of Governors of the Research Triangle Institute.
Ms. Pelletier has been the Chief Executive Officer and President of Evofem Biosciences since February 2013. Ms. Pelletier is an expert in global marketing, having launched pharma brands worldwide at Fortune 500 companies, such as GD Searle and Women First Healthcare. Following the sale of GD Searle, Ms. Pelletier became the Vice President of Women First Healthcare, a position she held for 4 years, after which the company underwent an asset divestiture. Subsequently, Ms. Pelletier founded her own consulting business, Saundra Pelletier International, a business she developed as an executive coach and keynote speaker. In 2009, Ms. Pelletier founded WomanCare Global, a non-profit organization for women’s healthcare, where she currently serves as its CEO.
Ms. Pelletier holds a BA in Business from Husson University, and a BA in Communications from New England School of Communications, and continues to be a board member of Women Deliver and Willows Foundation, a member of Athena, and a trustee of Husson University.